文献速递肿瘤 PET/CT

FSPG与FDG PET/CT检测胰腺导管腺癌转移的前瞻性对比验证研究

Prospective comparison of (4S)-4-(3-18F-fluoropropyl)-L-glutamate versus 18F-fluorodeoxyglucose PET/CT for detecting metastases from pancreatic ductal adenocarcinoma: a proof-of-concept study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-01-11

该概念验证研究在7只PDAC荷瘤小鼠和23例组织确诊的III或IV期PDAC患者中,前瞻性对比FSPG与FDG PET/CT检测转移的性能。动物模型中FSPG更早发现更多转移;患者分析中FSPG灵敏度、特异度和准确率呈更高趋势,病灶分析中FSPG检出转移灶显著更多(109 vs 95,P=0.0001)。

要点

  • FSPG PET检测PDAC转移的灵敏度、特异度和准确率呈高于FDG PET的趋势。
  • 病灶分析中FSPG检出转移灶显著多于FDG(109 vs 95,P=0.0001)。
  • FSPG肝本底低使肝转移图像更易判读,有助于检出肝转移。

核心结论

  • FSPG PET在检测转移性PDAC方面优于FDG PET,尤其在肝转移检出上。

研究设计与样本

  • 在7只PDAC荷瘤小鼠中行小动物PET对比FSPG与FDG。
  • 前瞻性纳入23例组织确诊的III或IV期PDAC患者行PET/CT。
  • PET/CT结果与组织病理学或3个月和6个月后增强CT结果进行关联。

主要发现

  • 动物模型中FSPG PET较FDG PET更早且持续发现更多PDAC转移。
  • 患者分析中FSPG与FDG的灵敏度、特异度和准确率分别为95.0%、100.0%、95.7%和90.0%、66.7%、90.0%。
  • 病灶分析中FSPG检出PDAC转移灶显著多于FDG(109 vs 95;P=0.0001,95%CI 4.9-14.6),尤其在肝脏。
  • 阳性扫描中FSPG与FDG的靶本比相似(FSPG 4.2±4.3,FDG 3.6±3.0;P=0.44,95%CI -1.11至0.48)。
  • FSPG阳性病灶的肿瘤最大标准化摄取值低于FDG(FSPG 4.2+2.3,FDG 7.7+5.7;P=0.002,95%CI 0.70-4.10)。

关键数值与推荐

  • 患者分析中FSPG PET灵敏度95.0%、特异度100.0%、准确率95.7%。
  • 患者分析中FDG PET灵敏度90.0%、特异度66.7%、准确率90.0%。
  • 病灶分析中FSPG检出109个转移灶,FDG检出95个(P=0.0001,95%CI 4.9-14.6)。

临床怎么用

  • FSPG PET可作为检测PDAC转移的候选显像方法,尤其针对肝转移。
  • FSPG肝本底活性低,图像判读较FDG更容易。

局限性

  • 研究为概念验证性质,动物样本为7只小鼠、患者样本为23例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: (4S)-4-(3-18F-Fluoropropyl)-L-glutamate (FSPG) positron emission tomography (PET) reflects system xC- transporter (xCT) expression. FSPG PET has been used to detect brain, lung, breast and liver cancer with only modest success. There is no report on the use of FSPG PET in pancreatic ductal adenocarcinoma (PDAC), presumably because of normal xCT expression in the pancreas. Nonetheless, the tissue-specific expression of xCT in the pancreas suggests that FSPG PET may be ideal for identifying metastasized PDAC. METHODS: The performance of FSPG in detecting PDAC metastases was compared with that of 18F-fluorodeoxyglucose (FDG) in small-animal PET studies in seven PDAC tumour-bearing mice and in prospective PET/computed tomography (CT) studies in 23 patients with tissue-confirmed PDAC of stage III or stage IV. All PET/CT results were correlated with the results of histopathology or contrast-enhanced CT (ceCT) performed 3 and 6 months later. RESULTS: In the rodent model, FSPG PET consistently found more PDAC metastases earlier than FDG PET. FSPG PET showed a trend for a higher sensitivity, specificity and diagnostic accuracy than FDG PET in detecting PDAC metastases in a patient-based analysis: 95.0%, 100.0% and 95.7%, and 90.0%, 66.7% and 90.0%, respectively. In a lesion-based analysis, FSPG PET identified significantly more PDAC metastases, especially in the liver, than FDG PET (109 vs. 95; P = 0.0001, 95% CI 4.9-14.6). The tumour-to-background ratios for FSPG and FDG uptake on positive scans were similar (FSPG 4.2 ± 4.3, FDG 3.6 ± 3.0; P = 0.44, 95% CI -1.11 to 0.48), despite a lower tumour maximum standardized uptake value in FSPG-avid lesions (FSPG 4.2 + 2.3, FDG 7.7 + 5.7; P = 0.002, 95% CI 0.70-4.10). Because of the lower physiological activity of FSPG in the liver, FSPG PET images of the liver are more easy to interpret than FDG PET images, and therefore the use of FSPG improves the detection of liver metastasis. CONCLUSION: FSPG PET is superior to FDG PET in detecting metastasized PDAC, especially in the liver.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Cheng MF, Huang YY, Ho BY, et al. Prospective comparison of (4S)-4-(3-18F-fluoropropyl)-L-glutamate versus 18F-fluorodeoxyglucose PET/CT for detecting metastases from pancreatic ductal adenocarcinoma: a proof-of-concept study. Eur J Nucl Med Mol Imaging. 2019. PMID: 30635754. doi:10.1007/s00259-018-4251-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。